BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30194485)

  • 1. POLE gene hotspot mutations in advanced pancreatic cancer.
    Guenther M; Veninga V; Kumbrink J; Haas M; Westphalen CB; Kruger S; Heinemann V; Kirchner T; Boeck S; Jung A; Ormanns S
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2161-2166. PubMed ID: 30194485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
    Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
    Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotype of POLE-mutated endometrial cancer.
    Imboden S; Nastic D; Ghaderi M; Rydberg F; Rau TT; Mueller MD; Epstein E; Carlson JW
    PLoS One; 2019; 14(3):e0214318. PubMed ID: 30917185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
    McConechy MK; Talhouk A; Leung S; Chiu D; Yang W; Senz J; Reha-Krantz LJ; Lee CH; Huntsman DG; Gilks CB; McAlpine JN
    Clin Cancer Res; 2016 Jun; 22(12):2865-73. PubMed ID: 26763250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer.
    Wang OH; Azizian N; Guo M; Capello M; Deng D; Zang F; Fry J; Katz MH; Fleming JB; Lee JE; Wolff RA; Hanash S; Wang H; Maitra A
    PLoS One; 2016; 11(3):e0152300. PubMed ID: 27023625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.
    Singh P; Srinivasan R; Wig JD
    Pancreas; 2012 May; 41(4):541-6. PubMed ID: 22504380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction.
    Li Y; Bian Y; Wang K; Wan XP
    BMC Med Genet; 2019 Dec; 20(1):202. PubMed ID: 31864301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medullary Pancreatic Carcinoma Due to Somatic POLE Mutation: A Distinctive Pancreatic Carcinoma With Marked Long-Term Survival.
    Kryklyva V; Ter Linden E; Kroeze LI; de Voer RM; van der Kolk BM; Stommel MWJ; Hermans JJ; Luchini C; Wood LD; Hruban RH; Nagtegaal ID; Ligtenberg MJL; Brosens LAA
    Pancreas; 2020 Aug; 49(7):999-1003. PubMed ID: 32658072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
    Espinosa I; Lee CH; D'Angelo E; Palacios J; Prat J
    Am J Surg Pathol; 2017 Aug; 41(8):1121-1128. PubMed ID: 28498284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
    Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
    Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials.
    Ormanns S; Haas M; Baechmann S; Altendorf-Hofmann A; Remold A; Quietzsch D; Clemens MR; Bentz M; Geissler M; Lambertz H; Kruger S; Kirchner T; Heinemann V; Boeck S
    Br J Cancer; 2016 Dec; 115(12):1520-1529. PubMed ID: 27802454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
    Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
    Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer.
    Yi Q; Dong F; Lin L; Liu Q; Chen S; Gao F; He Q
    Tumour Biol; 2016 May; 37(5):5805-10. PubMed ID: 26546433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of hotspot exonuclease domain mutations in the DNA polymerase ϵ gene in endometrial cancer.
    Tian W; Ji Z; Wang J; Meng J; Bi R; Ren Y; Shan B; Yang G; Wang H
    Front Oncol; 2022; 12():1018034. PubMed ID: 36313640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
    Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
    Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.